ICCS 2024 | Seattle, WA

Home
Conference Program

Conference Program

The Course will only be offered in-person.
The Meeting will be available both in-person and virtually.

All program times are listed in Pacific Time zone.

COURSE DATES
Friday, October 4 - Sunday, October 6
The course is scheduled to finish at noon (12pm) on Sunday, October 6.

MEETING DATES
Sunday, October 6 - Tuesday, October 8
The meeting will offically start Sunday, after the corporate workshops, at 2pm.

Fri - Oct 02

Sat - Oct 03

Sun - Oct 04

Mon - Oct 05

Tue - Oct 06

View Summary Only

Sunday, October 4th

7:00 - 8:00 AM
Ancillary Event

BECKMAN COULTER USER GROUP

Acapella 1

7:30 - 8:00 AM
Breakfast

BREAKFAST

Overture Foyer

8:00 - 11:50 AM
Course

COURSE SUNDAY AM

Symphony 1

8:00

Automation
Leo Lin.

8:45

T/NK Cell Neoplasms
Erik Ames.

9:45

Coffee Break
.

10:00

Plasma Cell Neoplasms
Mike Linden.

10:45

Future of flow - AI
Joe DiGiuseppe.

11:20

Speaker Forum
.

11:40

Wrap Up - Part 1
Mike Linden.

11:45

Wrap Up - Part 2
Valerie Miller.

12:30 - 2:30 PM
Corporate Workshop

CORPORATE WORKSHOPS (IN-PERSON MEETING ATTENDEES ONLY)
Chair/Organizer: Jolene Cardinali

Concerto A

12:30

Sysmex America
.

1:00

Waters Biosciences (BD)
.

1:30

Beckman Coulter Life Sciences
.

2:00

Cytek Biosciences, Inc.
.

12:30 - 1:30 PM
Corporate Workshop

ON DEMAND CORPORATE WORKSHOP - SLINGSHOT BIO

On Demand 2

ON DEMAND CORPORATE WORKSHOP - STRECK

On Demand 2

2:30 - 5:15 PM
Plenary

MEETING WELCOME & PLENARY 1 -REGULATORY/ADMINISTRATION - REGULATORY ASPECTS WITH IMPACT ON CLINICAL FLOW CYTOMETRY
Chair/Organizer: Bruce Greig, Katie DeVitt

Symphony 1

2:30

Welcome
Wolfgang Kern.

2:45

CSI Case
Aaron Wilk.

3:00

Publishing in the Age of Artificial Intelligence
Fred Preffer.

3:20

Modernizing CLIA (Clinical Laboratory Improvement Amendments of 1988)
Gerald E Marti.

3:50

Exhibits & Coffee Break
.

4:20

Understanding the Intent of the CAP Flow Cytometry Checklist- Part 1
Giovanni Insuasti.

4:35

Understanding the Intent of the CAP Flow Cytometry Checklist- Part 2
Samreen Fathima.

4:50

CLSI Standards Updates: H42 and H43- Part 1
Katie Devitt.

5:00

CLSI Standards Updates: H42 and H43 - Part 2
Wolfgang Kern.

5:15 - 6:00 PM
Keynote

WALLACE H. COULTER LECTURE
Chair/Organizer: Wolfgang Kern

Symphony 1

5:15

WALLACE H. COULTER LECTURE
Joe DiGiuseppe.

6:00 - 7:30 PM
Posters/Exhibits

POSTER SESSION 1 & EXHIBIT RECEPTION (click to view) (click to close)

Symphony 2-4

100

Approach to Resolving T Cell Subset Assays Flagged for Director Review: A Single-Center Experience
Tori Catey, Valerie Miller, Dick Hwang, Jonathan Fromm, Sindhu Cherian, Fabienne Lucas. University of Washington, Department of Laboratory Medicine and Pathology, Seattle, WA, USA

101

Development Of A Dried-Down 14-Color Cocktail Improves Workflow Efficiency And Produces Consistent Results For Spectral Flow Cytometry
Qing Chang¹, Qing Chen², Juan Miao², Junwei Xin², Emily Bui¹, Jun Deng¹. ¹Cytek Biosciences, Inc., Fremont, CA, USA.²Cytek Biosciences China, Wuxi, China

102

Non-negative matrix factorization for automated multiple autofluorescence extraction in spectral flow cytometry
Dustin DeMeo, Jean Oak, Erik Ames, Aaron Wilk. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA

103

Validation of a 29-Color 31 antigen Single-Tube Flow Cytometric Assay for Integrated B, T, and Hodgkin Lymphoma Evaluation
Sary El Daker, Jennifer Reminick, Xiaotian Sun, Qi Gao, Roshal Mikhail. Memorial Sloan Kettering Cancer Center, New York, NY, USA

104

Validation of a 10-Color Flow Cytometry Assay Incorporating CD48 to Enhance the Diagnostic Accuracy and Minimal Residual Disease (MRD) Detection of T-Cell Acute Lymphoblastic Leukaemia (T-ALL)
Sheryll Gamatan, Jenny Li Bei, Ling Yang, Cheryl Lim, Eunice Lai, Stephrene Chan, Te Chih Liu, Shir Ying Lee. Division of Haematology, Department of Laboratory Medicine, National University Hospital, Singapore, Singapore

105

Transfer and Validation of the Ozette PIP-01 48-Marker Immune Profiling Panel at Cerba Research for Global Clinical Trials
Sanaz Koosha¹, Manpreet Singh¹, Matthias De Decker¹, Amber Baele¹, Eva Van Lombergen¹, Bieke Soen¹, Nithianandan Selliah¹, Kirsteen Maclean², Kurt VanGunst², Denise Allen², George Duma², Arpan Neupane², Cherie Green². ¹Cerba Research, New Hyde Park, NY, USA.²Ozette Technologies, Inc, Seattle, WA, USA

106

Emergency Hematopoiesis: distinguishing the normal from the abnormal through proposed criteria using flow cytometry
Angeliki Kotsiafti¹, Georgios Oudatzis¹, Maroula Milaiou¹, Aikaterini Mandaraka¹, Paraskevi Vasileiou², Georgios Paterakis¹. ¹Department of Immunology, Athens General Hospital âG. Gennimatasâ, Athens, Greece.²Â«FlowdiagnosisÂ» Diagnostic Center, Athens, Greece

107

Evaluation of Interacting Cells in Peripheral Blood by Flow Cytometry: an Understudied Attribute of Human Biology
Chip Lomas, Scott Bornheimer, Aaron Middlebrook. Waters Biosciences, Milpitas, CA, USA

108

Study of manual vs. automated cocktail preparation using AssayMate Cocktail Prep Workstation for spectral flow cytometry.
David PILLON¹, Lu Wen², Zayda Piedra-Quintero¹, Kevin Bowditch¹, Isabelle Viellard Pelve, ². ¹BioLegend Inc, San Diego, CA, USA.²Revvity Health Sciences, Inc, Waltham, MA, USA

109

The influencing factors of high-throughput CBA method for detecting cytokines and the performance verification of the detection
Liyuan Qiu, Dongchu Wang, Hui Wang. Hebei Yanda Lu Daopei Hospital, Langfang, China

110

Development of a CD20 Flow Cytometry Assay in Whole Blood for Anti-CD20 Therapy Monitoring on BD FACSLyric
Eugene V. Ravkov¹, Patricia M. Davis¹, Jenifer D. De Juan², Swapna Gudipaty¹, Garrin V. Abbott², David P. Ng^{1, 3}, Leo Lin^{1, 3}. ¹ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA.²Immunologic Flow Cytometry, ARUP laboratories, Salt Lake City, UT, USA.³Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA

111

Bulk Ammonium Chloride Lysis for Routine Diagnostic Plasma Cell Flow Cytometry: A Single-Center Validation and Twelve-Month Post-Implementation Review
Laura Rodriguez-Torres¹, Nour Shurbaji¹, Duaa Dabbour¹, Evgeniya Shin¹, Kelly Heinstein¹, Robert Liwski^{1, 2}. ¹Nova Scotia Health Authority, Halifax, NS, Canada.²Dalhousie University, Halifax, NS, Canada

112

Validation of a 12-Color Flow Cytometry Assay for Quantitative Assessment of CD123 in AML and MDS
Nithianandan Selliah¹, Leen Catrysse², Rowan Claeys², Amber Baele², Bieke Soen². ¹Cerba Research, Lake Success, NY, USA.²Cerba Research, Ghent, Belgium

114

Exclusion of immature and dysfunctional granulocytes improves diagnostic specificity of neutrophil oxidative burst assay
Ananyaa Srinivasan, Jean Oak, Aaron Wilk. Department of Pathology, Stanford University School of Medicine, Palo Alto, CA, USA

115

CLL/SLL with Atypical Immunophenotype: An Integrated Diagnostic Approach
Wei J. Wang¹, Wei Wang². ¹City of Hope National Medical Center, Duarte, CA, USA.²MD Anderson Cancer Center, Houston, TX, USA

116

Verification of CD40 Ligand clinical flow cytometry assay from FACSCanto II to FACSLyric.
Casey B Wells, Xiaomeng Ren, Miguel FS Ventura, Rebecca A Marsh. Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

118

Utility of Natural Killer (NK)-Cell Receptor Expression on γδ T-Cells in Differentiating Reactive and Neoplastic γδ T-Cell Populations
Valerie A Woodings, Orrin Koepke, Jason E Love, Alireza Torabi, Jonathan R Fromm, Sindhu Cherian, Afshin Shameli. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA

119

Assay Transfer of Two Tube 12-Color T-Cell Function Panels Adapted to Include CAR Detection Using a BD FACSLyric™ Flow Cytometer
Yang Zeng, Farzad Oreizy, Angela Chen, Chih-Hung Lai, Rodrigo Pestana Lopes. Waters Biosciences, Milpitas, CA, USA

120

Standardized 35-Parameter Mass Cytometry Immune Profiling Workflow and Cohort-Derived Reference Intervals for Healthy Adults Using the PLT-MC601 Platform
Huifang Zhao¹, Man Chen², Hui Wang¹. ¹Hebei Yanda Lu Daopei Hospital, Langfang, China.²Beijing Lu Daopei Hospital, Beijing, China

121

Impact of Staining Method on CD16 PerCPCy5.5 Expression
Gemma Zydowsky, MLS (ASCP), Jenny Byrd, MS, SCYM (ASCP). University of Wisconsin Hospital and Clinics, Madison, WI, USA

122

CD34 Negative Acute Leukemia, Mediastinal Mass and TP53 Mutation: An Aggressive Presentation of a Rare Entity
Shreyam Acharya, Anirban Kundu, Atoshi Basu, Sudhanya Biswas, Debmalya Bhattacharyya. Apollo Multispeciality Hospitals, Kolkata, India

124

When the Bone Marrow Is Negative: Flow Cytometric Diagnosis of Isolated CNS Blast Phase in CML
Charles Ehster, Brianna Cunniff-Caswell, Michael Linden, Samreen Fathima. University of Minnesota, Minneapolis, MN, USA

125

Blastic Plasmacytoid Dendritic Cell Neoplasm with Loss of CD303: A Challenging Differential Diagnosis Remediated with IRF8 Flow Cytometric Analysis
Samuel F Van Buskirk, Alden E Chesney, Kyle Tripp, Rajeswari Jayakumar. Virginia Commonwealth University Health System, Richmond, VA, USA

126

Diagnostic Dilemma in Acute Leukemia
Alexander Yue, Daniel Ding. Walter Reed National Military Medical Center, Bethesda, MD, USA

127

Acute Myeloid Leukemia Mimicking Blastic Plasmacytoid Dendritic Cell Neoplasm
Dmitry Zlobin^{1, 2}, Carlos J Villarroel^{1, 2}, Deborah A Fuchs^{1, 2}. ¹University of Arizona, Department of Pathology and Laboratory Medicine, Tucson, AZ, USA.²Banner University Medical Center, Tucson, AZ, USA

128

58 Parameter Spectral Cytometry for Broad Clinical Diagnostic Application.
Evangelia Williams, Elisavet Ntavli, Eduardo de Paiva Alves, McKenzie Duncan, Thomas Hayday, Adam G. Laing. IMU Biosciences, London, United Kingdom

129

Cytoplasmic Immunoglobulin Light Chain–Based Gating for Plasma Cells: A No-Cost Alternative to CD38-Based Gating in Flow Cytometry
karthik Bommannan Bommannan Kuppuraju, Shirley Sundersingh. Cancer Institute (W.I.A), Chennai, India

130

Flow Features of Acute Promyelocytic Leukemia: A Single Institution Quality Improvement Project
Mahsa Hajizadeh, Elizabeth Courville. University of Virginia Health, Charlottesville, VA, USA

131

Flow Cytometric Immunophenotypic Variation in Adult T-Cell Leukemia / Lymphoma.
Matan Kadosh², Luis Ascanio Cortez¹, Alberto Paniz-Mondolfi¹, Wei Cai¹, Amy Duffield¹, Shafinaz Hussein¹. ¹Mount Sinai Hospital, Icahn School of Medicine, New York, NY, USA.²Mount Sinai West, New York, NY, USA

132

Memory-assisted interpretation of TCL1, against the B-cell maturation compartment in B-cell lymphoproliferative disorders
GEORGIOS PATERAKIS¹, ANGELIKI KOTSIAFTI¹, GEORGIOS OUDATZIS¹, MAROULA MILAIOU¹, KATERINA MANDARAKA¹, PARASKEVI VASILEIOU². ¹IMMUNOLOGY DEPARTMENT, ATHENS, Greece.²FLOWDIAGNOSIS DIAGNOSTIC LABORATORY, ATHENS, Greece

133

Visualizing Measurable Residual Disease: BD CellView™ Imaging confirms the Single-Cell Origin of Rare Abnormal Plasma Cells
Siobhan Cashman¹, Chip Lomas², Aaron Middlebrook², Scott Bornheimer². ¹Waters Biosciences, Limerick, Ireland.²Waters Biosciences, Milpitas, CA, USA

134

Analytical Performance of an Automated Dry Tube Workflow Using the CellMek SPS system
Xizi (Daisy) Dai, Juan Fernandez De Castro, Xue Wen, Jessica Ashbaugh, Sandra Hernandez. Beckman Coulter Life Sciences, Miami, FL, USA

135

A Flexible Cloud Platform for Validated Flow Cytometry Workflows
Srikar Devakonda¹, Santosh Putta¹, Leesa Pennell¹, David Soper¹, Jansen Seheult², Pedro Horna². ¹Revvity Inc., San Diego, CA, USA.²Mayo Clinic, Rochester, MN, USA

136

Measurable residual disease: Positive next generation sequencing results with negative flow cytometry does not always indicate residual disease.
Tanvi/YP Verma, Xueyan Chen, Emily/H Glynn, Cecilia/CS Yeung, Sindhu Cherian, Kerstin Edlefsen. University of Washington, Seattle, WA, USA

137

Development and Validation of the BD Horizon RealDye™ Portfolio for Conventional and Spectral Flow Cytometry: Combining Advanced Fluorochrome Performance with Manufacturing Excellence
Lorena Hidalgo¹, Feng-Jun Luan¹, Jessica Stokes¹, Andrea Nguyen¹, Hyunji Do¹, Saloni Desai¹, Stephanie Widmann¹, Peter Mage², Jacob Rabenstein¹. ¹Waters Biosciences, San Diego, CA, USA.²Waters Biosciences, Milpitas, CA, USA

138

Can a Novel Stabilizing Reagent Preserve Ex-Vivo Platelet Activation States for Seven-Day Delayed Flow Cytometry Analysis?
Yuqian Hua¹, Kelvin Liu², Xingzhou Liu², Zhaohui Wang². ¹IntelliFlow (Beijing) Biotechnology Co., Ltd., Beijing, China.²Gene tech ents Ltd., Princeton, NJ, USA

139

Automated Flow Cytometry sample preparation: Validation of Wash/Stain/Lysis/Wash protocol on CellMek sample preparation system
Taruna Jagtiani¹, Yijie Liu^{1, 2}, Jeffrey Wilks¹. ¹Clinical Flow Cytometry Laboratory, Department of Pathology, Northwestern Memorial Hospital, Chicago, IL, USA.²Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

140

Single RNA Molecule Detection in Intact Cells by Flow Cytometry Using the superRCA Assay
Josefine Lustig¹, Sofie Kelleway², Lei Chen¹, Amey Mukim¹. ¹Rarity Bioscience AB, Uppsala, Sweden.²University of Nottingham, Nortingham, United Kingdom

141

Ultra-Sensitive FMC63 CAR-T Monitoring Using the superRCA Assay
Amey Mukim, Thomas Edgren, Lei Chen. Rarity BIoscience, Uppsala, Sweden

142

A Label-Free Foundation Model for Automated Viability Assessment and Functional Assays in Imaging Flow Cytometry
Keegan Owsley¹, Greg Fields¹, Siobhan Cashman², Seamus Hickey². ¹Waters Biosciences, Milpitas, CA, USA.²Waters Biosciences, Limerick, Ireland

143

UltraSensitive superRCA Assay Enables Detection of KIT D816V Beyond ddPCR
Natalia Sigal¹, Andrew Dixon¹, Erik Kish-Trier¹, Mark Rosenzweig ², Guang Yang², Rentian Wu², Rachel L Erlich², Lei Chen³, Sara Bodbin³, Tracy I George¹, Leo Lin¹, Peng Li¹. ¹ARUP Laboratories, Salt Lake City, UT, USA.²Blueprint Medicines, Cambridge, MA, USA.³Rarity Bioscience, Uppsala, Sweden

144

Clinical Validation and Implementation of a Custom Automation Platform for Clinical Flow Cytometry Specimen Preparation
Xiaotian Sun¹, Sary EI Daker¹, Brian Murphy², Mohamad Haque³, Jennifer Reminick¹, Qi Gao¹, Mikhail Roshal¹. ¹Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.²Pathology Automation, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.³Bioinformatics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

145

Implementing Automated Tissue Dissociation in Clinical Flow Cytometry: Improved Cell Recovery and Diagnostic Yield
Helena Varela de Araujo, Bruce Loewen, Jing-Ping Zhang, Dionicy Tarantino, Ryan Labonte, Bartosz Grzywacz. Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA, USA

146

Detector Setting Independent (DSI) scaling on the BD FACSDiscover™ A7 Cell Analyzer
Joshua Welsh, Tri Le, Chip Lomas, Aaron Middlebrook. Waters Biosciences, Milpitas, CA, USA

147

Automated Sample Preparation for 25-Color Flow Cytometric Immunophenotyping of Human PBMCs
Yan Lu¹, Xiaohuan Wang¹, Ming Lei¹, Alex Ko², Garret Guenther², Peifang Ye¹, Nancy Li². ¹Agilent Biosciences (Hangzhou) Co., Ltd., Hangzhou, China.²Agilent Technologies Inc., La Jolla, CA, USA

7:30 - 8:30 PM
Ancillary Event

CAREER LAB (OPEN TO ALL ICCS MEMBERS)

Symphony 1

Financial compensation remains one of the least discussed yet most important aspects of professional development, and compensation structures, promotion pathways, and recognition processes vary substantially across institutions and countries. Building on the highly interactive format of the ICCS Career Lab, this session explores how cytometrists can better understand compensation systems and communicate the measurable value they bring to their organizations. Through career storytelling, audience polling, compensation data review, and facilitated discussion, participants will gain practical insights to support salary discussions, promotion efforts, and long-term career planning.